Last reviewed · How we verify
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is a Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma. The purpose is to investigate the efficacy and safety of this therapeutic regimen to reduce the risk of postoperative recurrence in resectable HCC patients with a high risk of recurrence.
Details
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 54 |
| Start date | Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Resectable Hepatocellular Carcinoma
Interventions
- Cadonilimab
- TACE
- Surgery